IRCT20110510006431N6尚未招募3 期
Evaluation of the effects of alpha-1-antitrypsin on the progression of covid-19 disease: a randomized control trial
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Age above 18 years
- •The presence of shortness of breath
- •Positive PCR test for corona or lung involvement in imaging
- •Signing informed consent and readiness to participate in the plan
排除标准
- •Patients suffering from underlying diseases including pulmonary hypertension, kidney failure, seizures, depression, chronic hepatitis, cirrhosis and cholestatic liver diseases and pulmonary embolism (in the past 3 months)
- •Use of anti-coagulant drugs such as warfarin, hormonal drugs and other illegal drugs (within the past 30 days)
- •Alcohol consumption
- •Pregnancy or breastfeeding
- •Allergy to AAT drug
- •Having IgA deficiency
- •No smoking in the last 6 months
研究者
相似试验
已完成
1 期
The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 DiabetesDiabetesType 1 DiabetesNCT01319331University of Colorado, Denver12
终止
1 期
A Research Trial of Aralast in New Onset Diabetes (RETAIN)Diabetes Mellitus, Type 1NCT01183468National Institute of Allergy and Infectious Diseases (NIAID)17
已完成
不适用
Prevalence of Alpha-1 Antitrypsin Dysfunction in Pulmonary EmphysemaPulmonary EmphysemaNCT02382367Hospices Civils de Lyon190
已完成
2 期
Effect of Infliximab on treatment of cirrhosis.Cryptogenic cirrhosis.Other and unspecified cirrhosis of liverIRCT2016052228003N1Research center for infectious diseases of digestive system, research adjutancy of Ahvaz Jundishapur30
撤回
2 期
A Research Trial of Aralast NP in New Onset Diabetes (RETAIN) - Part IIDiabetes Mellitus, Type 1NCT01183455National Institute of Allergy and Infectious Diseases (NIAID)